Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction

Circulation

Volumn 99, Issue 6, 1999, Pages 786-792

  Richards, A Mark ^a   Doughty, R ^a   Nicholls, M G ^a   Macmahon, S ^a   Ikram, H ^a   Sharpe, N ^a   Espiner, E A ^a   Frampton, C ^a   Yandle, T G ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Heart failure; Natriuretic peptides; Norepinephrine

Indexed keywords

ARGIPRESSIN; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; NEUROHORMONE; NORADRENALIN; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HORMONE BLOOD LEVEL; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0032939391     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.99.6.786     Document Type: Article

References (25)

1. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819-823.
2. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, Kubo SH, Rudin-Toretsky E, Yusuf S. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the studies of left ventricular dysfunction (SOLVD). Circulation. 1990;82:1724-1729.
3. Rouleau JL, de Champlain J, Klein M, Bichet D, Moyé L, Packer M, Dagenais GR, Sussex B, Arnold JM, Sestier F, Parker JO, McEwan P, Bernstein V, Cuddy E, Lamas G, Gottlieb SS, McCans J, Nadeau C, Delage F, Hamm P, Pfeffer MA. Activation of neurohumoral systems in postinfarction left ventricular dysfunction. J Am Coll Cardiol. 1993;22: 390-398.
4. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A, for the V-HeFT VA Cooperative Studies Group. Plasma norepinephrine, plasma renin activity, and congestive heart failure: relations to survival and the effects of therapy in V-HeFT II. Circulation 1993;87(suppl VI):VI-40-VI-48.
5. Omland T, Aakvaag A, Bonarjee VVS, Caidahl K, Lie RT, Nilsen DW, Sundsfjord JA, Dickstein K. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Circulation. 1996;93:1963-1969.
6. Arakawa N, Nakamura M, Aoki H, Hiramcri K. Plasma brain natriuretic peptide concentrations predict survival after acute myocardial infarction. J Am Coll Cardiol. 1996;27:1656-1661.
7. Australia-New Zealand Heart Failure Research Collaborative Group. Effects of carvedilol, a vasodilator-β-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation. 1995;92:212-218.
8. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet. 1997;349: 375-380.
9. Yandle T, Espiner E, Nicholls M, Duff H. Radioimmunoassay and characterisation of atrial natriuretic peptide in human plasma. J Clin Endocrinol Metab. 1986;61:71-78.
10. Yandle TG, Richards AM, Gilbert A, Fisher S, Holmes S, Espiner EA. Assay of brain natriuretic peptide (BNP) in human plasma: evidence for high molecular weight BNP as a major plasma component in heart failure. J Clin Endocrinol Metab. 1993;76:832-838.
11. Goldstein DS, Feurstein G, Izzo JL, Kopin JJ, Keiser HR. Validity and reliability of liquid chromatography with electrochemical detection for measuring plasma levels of norepinephrine and epinephrine in man. Life Sci. 1981;28:467-475.
12. Sadler WA, Lynskey C, Gilchrist N, Espiner EA, Nicholls MG. A sensitive radioimmunoassay for measuring plasma antidiuretic hormone in man. N Z Med J. 1983;96:959-963.
13. Packer M, Bristow MR, Cohn J, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH, for the US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349-1355.
14. Packer M, Colucci WS, Sackner-Bernstein JD, Liang C-S, Goldscher DA, Freeman I, Kukin ML, Kinhal V, Udelson JE, Klapholz M, Gottlieb SS, Pearle D, Cody RJ, Gregory JJ, Kantrowitz NE, LeJemtel TH, Young ST, Lukmas MA, Shusterman NH, for the PRECISE Study Group. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: the PRECISE Trial. Circulation. 1996; 94:2793-2799.
15. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N, for the MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 1996;94:2807-2816.
16. Vantrimpont P, Rouleau JL, Wun C-C, Ciampi A, Klein M, Sussex B, Arnold MO, Moye L, Pfeffer M, for the SAVE Investigators. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. J Am Coll Cardiol. 1997;29:229-236.
17. Rundqvist B, Elam M, Bergmann-Sverrisdottir Y, Eisenhofer G, Friberg P. Increased cardiac adrenergic drive precedes generalized sympathetic activation in human heart failure. Circulation. 1997;95:169-175.
18. Nakaoka H, Kitahara Y, Amano M, Imataka K, Fujii J, Ishibashi M, Yamaji T. Effect of β-adrenergic receptor blockade on atrial natriuretic peptide in essential hypertension. Hypertension. 1987;10:221-225.
19. Yoshimoto T, Naruse M, Tanabe A, Naruse K, Seki T, Imaki T, Muraki T, Matsuda Y, Demura H. Potentiation of natriuretic peptide action by the β-adrenergic blocker carvedilol in hypertensive rats: a new antihypertensive mechanism. Endocrinology. 1998;139:81-88.
20. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation. 990;82:1730-1736.
21. Rouleau J-L, Packer M, Moyé L, de Champlain J, Bichet D, Klein M, Rouleau JR, Sussex B, Arnold JM, Sestier F, Parker JO, McEwan P, Bernstein V, Cuddy TE, Lamas G, Gottlieb SS, McCans J, Nadeau C, Delage F, Wun C-C, Pfeffer MA. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol. 1994;24:583-591.
22. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D, Ohnishi M, Sugimoto Y, Kinoshita M. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation. 1997;96:509-516.
23. Richards AM, Nicholls MG, Yandle TG, Frampton C, Espiner EA, Turner JG, Buttimore RC, Lainchbury JG, Elliott JM, Ikram H, Crozier IG, Smyth DW. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation. 1998;97: 1921-1929.
24. Nelesen RA, Dimsdale JE, Ziegler MG. Plasma atrial natriuretic peptide is unstable under most storage conditions. Circulation. 1992;86:463-466.
25. Buckley MG, Sagnella GA, MacGregor GA. Stability of atrial natriuretic peptide during storage at -20°C. J Hum Hypertens. 1996;10:431-432.